Drug Profile
Latanoprost formulation - ISTA Pharmaceuticals/Senju
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Senju Pharmaceutical
- Developer ISTA Pharmaceuticals
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 06 Jun 2012 ISTA Pharmaceuticals has been acquired by Bausch & Lomb
- 29 Oct 2007 Phase-I clinical trials in Glaucoma in USA (unspecified route)
- 29 Jun 2006 Preclinical trials in Glaucoma in Japan (unspecified route)